LRND—NYLI U.S. Large Cap R&D Leaders ETF[†]

Formerly IQ U.S. Large Cap R&D Leaders ETF

All data as of 3/31/25

Fund description: The Fund seeks investment results that track, before fees and expenses, the price and yield performance of the NYLI U.S. Large Cap R&D Leaders Index, an index that seeks to provide exposure to innovative companies by investing in U.S. large-cap equity securities of companies that have high research and development (R&D) spending.

Growth potential through innovation

Gain exposure to innovative companies with a history of reinvesting into research and development (R&D), exhibiting strong growth potential.

A passive approach to R&D

The Fund's growth screening employs a simple, yet defined approach to identify innovative companies based upon current metrics.

SI - Since Fund Incontion (02/08/2022)

A core growth position

Companies with significant reinvestment into R&D can help investors seek favorable relative performance and attractive future growth potential.

Average Annual Total Returns (%)

Average Annual Total Netarns (70)	age Airitaan Total Netariis (70)					312022)	
	QTR	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	SI
NYLI U.S. Large Cap R&D Leaders ETF (NAV)	-5.57	-5.57	3.36	9.82	-	-	9.88
NYLI U.S. Large Cap R&D Leaders ETF (MP)	-5.91	-5.91	3.11	9.93	-	-	9.88
NYLI U.S. Large Cap R&D Leaders Index	-5.54	-5.54	3.51	9.93	-	-	9.98
Russell 1000 Growth Index ²	-9.97	-9.97	7.76	10.10	20.09	15.12	10.08

Calendar Year Returns (%)

	2024 2023
NYLI U.S. Large Cap R&D Leaders ETF (NAV)	21.59 44.05
NYLI U.S. Large Cap R&D Leaders ETF (MP)	21.92 44.18
NYLI U.S. Large Cap R&D Leaders Index	21.79 44.13
Russell 1000 Growth Index ²	33.36 42.68

Returns represent past performance which is no guarantee of future results. Current performance may be lower or higher. Investment return and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Performance reflects a contractual fee waiver and/or expense limitation agreement in effect until terminated by the board of Trustees of the ETF, without which total returns may have been lower. Visit newyorklifeinvestments.com for the most recent month-end performance. Expenses stated are as of the fund's most recent prospectus.

Portfolio data as of 3/31/25. Percentages based on total net assets and may change daily.

Top Holdings¹ (%)

1 op Holalingo (70)		
Amazon.com, Inc.	8.15	
Alphabet Inc.	7.74	
Meta Platforms, Inc.	6.64	
Apple Inc.	5.50	
Microsoft Corporation	5.26	
Intel Corporation	3.90	
Merck & Co., Inc.	3.83	
Johnson & Johnson	3.79	
Eli Lilly and Company	2.28	
Bristol-Myers Squibb Company	2.09	

Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Total Returns are calculated using the daily 4:00 pm ET net asset value (NAV). The price used to calculate the market price returns ("MP") is the mean between the day's last bid and ask prices on the fund's primary exchange. The market price returns do not represent returns an investor would receive if shares were traded at other times.

Index performance is for illustrative purposes only and does not represent actual Fund performance. One cannot invest directly in an index. Performance data for the Index assumes reinvestment of dividends and is net of the management fees for the Index's components, as applicable, but it does not reflect management fees, transaction costs or other expenses that you would pay if you invested in the Fund directly. No representation is being made that any investment will achieve performance similar to that shown.

†Effective 8/28/24, IQ U.S. Large Cap R&D Leaders ETF was renamed NYLI U.S. Large Cap R&D Leaders ETF.

The Momingstar Medalist Ratings are not statements of fact, nor are they credit or risk ratings. The Momingstar Medalist Rating (i) should not be used as the sole basis in evaluating an investment product, (ii) involves unknown risks and uncertainties which may cause expectations not to occur or to differ significantly from what was expected, (iii) are not guaranteed to be based on complete or accurate assumptions or models when determined algorithmically, (iv) involve the risk that the return target will not be met due to such things as unforeseen changes in changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rates, exchange rate changes, and/or changes in political and social conditions, and (v) should not be considered an offer or solicitation to buy or sell the investment product. A change in the fundamental factors underlying the Morningstar Medalist Rating can mean that the rating is subsequently no longer accurate.

Morningstar Ratings³

as of 3/31/25





Overall Morningstar Rating™ based on the risk-adjusted returns from among 1272 Large Blend funds.

	Stars	# of Funds
3 Yr	4	1272
Fund Deta	ils	
Ticker		LRND
Stock Excha	nge	NYSE Arca
Inception Da	te	02/08/2022
Total Net As	sets	\$8.03 M
Morningstar	Category	Large Blend
Benchmark	١	NYLI U.S. Large Cap R&D
		Leaders Index
Number of H		101
	rerage Market Cap	\$916.93 B
Price/Earnin	•	23.30
Price/Book V	/alue	3.68
Fund Expe	enses*	
Managemen	t Fee	0.14%
Other Expen	ses	0.01%
Total Annua	al Fund Operating Expe	enses 0.15%
Expense Wa	iver/Reimbursement	0.01%
	al Fund Operating Expe r/Reimbursement	enses 0.14%
Index Deta	ils	
Ticker		IQLCRNDT
Inception Da	te	11/30/2021
*As stated in	n the Fund's prospectus	the management fee of

*As stated in the Fund's prospectus, the management fee of 0.14% is to cover expenses incurred in connection with managing the portfolio.

Not FDIC/NCUA Insured | Not a Deposit | May Lose Value | No Bank Guarantee | Not Insured by Any Government Agency



NYLI U.S. Large Cap R&D Leaders ETF

Sector Weightings¹ (%) 36 25% Information Technology 26.67% Health Care Communication Services 16.38% Consumer Discretionary 14.28% Industrials 5.07% Financials 0.78% Consumer Staples 0.40% 0.30% Materials

Before considering an investment in the Fund, you should understand that you could lose money.

Principal Risks

Equity Securities Risk

Before You Invest

Investments in common stocks and other equity securities are particularly subject to the risk of changes in investors' perceptions of the financial condition of an issuer, conditions affecting equity markets generally and political and/or economic events. Equity prices may also be particularly sensitive to rising interest rates, as the cost of capital rises and borrowing costs increase.

Large-Capitalization Companies Risk

Large-capitalization companies may be less able than smaller capitalization companies to adapt to changing market conditions. Large-capitalization companies may be more mature and subject to more limited growth potential compared with smaller capitalization companies. During different market cycles, the performance of large-capitalization companies has trailed the overall performance of the broader securities markets.

Non-Diversified Risk

The Fund is classified as a "non-diversified" investment company under the Investment Company Act of 1940 (the "1940 Act"), which means it may invest a larger percentage of its assets in a smaller number of issuers than a diversified fund. To the extent the Fund invests its assets in a smaller number of issuers, the Fund will be more susceptible to negative events affecting those issuers than a diversified fund.

Industry/Sector Concentration Risk

The Fund's investment of a large percentage of its assets in the securities of issuers within the same industry or sector means that an adverse economic, business or political development may affect the value of the Fund's investments more than if the Fund were more broadly diversified. A concentration makes the Fund more susceptible to any single occurrence and may subject the Fund to greater market risk than a fund that is not so concentrated.

The NYLI U.S. Large Cap R&D Leaders Index seeks to provide exposure to highly innovative companies through the selection of Large-cap equities with the highest R&D spending in the past one year. Companies with high R&D spending are investing for future growth in their business and may enjoy strong long-term competitive positioning.

The Russell 1000® Growth Index measures the performance of the large-cap growth segment of the U.S. equity universe. It includes those Russell 1000® Index companies with higher price-to-book ratios and higher forecasted growth values.

The constituents of the Russell 1000® Index were used by New York Life Investment Management LLC ("NYLIM") as the starting universe for selection of the companies included in the NYLI U.S. Large Cap R&D Leaders Index. FTSE International Limited and its affiliates ("FTSE Russell") do not in any way create, calculate, maintain, review, sponsor, support, promote or endorse the NYLI U.S. Large Cap R&D Leaders Index or the NYLI U.S. Large Cap R&D Leaders ETF. In no event shall any FTSE Russell party have any liability for any direct, indirect, special, incidental, punitive, consequential (including without limitation lost profits) or any other damages in connection with the constituents of the Russell 1000® Index or the NYLI U.S. Large Cap R&D Leaders Index.

1. Percentages based on total net assets and subject to change without notice. 2. The Russell 1000® Growth Index is generally representative of the market sectors or types of investments in which the Fund invests. 3. The Momingstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Momingstar Risk Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance (this does not include the effects of sales charges, loads, and redemption fees). The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Momingstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Momingstar Rating metrics. The weights are: 100% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.

Price/Earnings Ratio is a valuation of a company's current share price compared to its per-share earnings and is not intended to demonstrate growth or income. Price/Book Ratio is used to compare a company's stock's value to its book value and is not intended to demonstrate growth or income.

© 2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future

The Momingstar Medalist Rating™ is the summary expression of Momingstar's forward-looking analysis of investment strategies as offered via specific vehicles using a rating scale of Gold, Silver, Bronze, Neutral, and Negative. The Medalist Ratings indicate which investments Momingstar believes are likely to outperform a relevant index or peer group average on a risk-adjusted basis over time. Investment products are evaluated on three key pillars (People, Parent, and Process) which, when coupled with a fee assessment, forms the basis for Morningstar's conviction in those products' investment merits and determines the Medalist Rating they're assigned. Pillar ratings take the form of Low, Below Average, Above Average, and High. Pillars may be evaluated via an analyst's qualitative assessment (either directly to a vehicle the analyst covers or indirectly when the pillar ratings of a covered vehicle are mapped to a related uncovered vehicle) or using algorithmic techniques. Vehicles are sorted by their expected performance into rating groups defined by their Momingstar Category and their active or passive status. When analysts directly cover a vehicle, they assign the three pillar ratings based on their qualitative assessment, subject to the oversight of the Analyst Rating Committee, and monitor and reevaluate them at least every 14 months. When the vehicles are covered either indirectly by analysts or by algorithm, the ratings are assigned monthly. For more detailed information about these ratings, including their methodology, please go to global.momingstar.com/managerdisclosures/.

Consider the Funds' investment objectives, risks, charges, and expenses carefully before investing. The prospectus and summary prospectus include this and other information about the Funds and are available by visiting the <u>Prospectus</u>. Read the prospectus carefully before investing.

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units", and otherwise, can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in-kind.

"New York Life Investments" is both a service mark, and the common trade name, of certain investment advisors affiliated with New York Life Insurance Company. Securities distributed by NYLIFE Distributors LLC, 30 Hudson Street, Jersey City, NJ 07302, Member FINRA/SIPC.

© 2025 NYLIM. All rights reserved. Any unauthorized use, disclosure, copying, dissemination, or redistribution of this information is strictly prohibited.